Business
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences Canada Ne...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health to Present at Two Upcoming Healthcare Investor Conferences\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, April 4, 2019\n\n\n\nLAVAL, QC, April 4, 2019 /CNW/ - BELLUS Health Inc. (TSX: BLU) (\"BELLUS Health\" or the \"Company\"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at two upcoming healthcare investor conferences.\nConference Presentation Details:\nEvent: Needham & Company 18th Annual Healthcare ConferenceDate/Time: Wednesday, April 10, 2019 at 3:30 p.m. ETLocation: New York, NY\nEvent: Bloom Burton & Co. Healthcare Investor ConferenceDate/Time: Wednesday, May 1, 2019 at 9:30 a.m. ETLocation: Toronto, ON\nLive webcasts from the Needham and Bloom Burton conference presentations may be accessed on the Events and Presentations page under the Investors & News section of the Company's website. Following the events, archived webcasts and presentations will be available on the BELLUS Health website.\nAbout BELLUS Health (www.bellushealth.com)\nBELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's lead drug candidate, BLU-5937, is being developed for the treatment of chronic cough. \nChronic cough is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with more than 2.6 million having unexplained or refractory chronic cough lasting for more than a year. There are limited treatment options for refractory chronic...